SurgiMab Competitors and Similar CompaniesClear all
SurgiMab's competitors and similar companies include Blue Earth Diagnostics, Microvascular Therapeutics, Curasight and vivoPharm.
 Microvascular Therapeutics Microvascular Therapeutics (MVT) is a biotechnology company engaged in the development of an ultrasound contrast agent, MVT-100. |  Curasight Curasight is a company engaged in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). | ||||
Founding Date | Founding Date 2011 | Founding Date 2014 | Founding Date 2016 | Founding Date 2013 | Founding Date 2003 |
Type | Type Private | Type Subsidiary | Type Private | Type Private | Type Subsidiary |
Tags | |||||
Locations | Locations Montpellier, FR HQ Grabels, FR | Locations Oxford, GB HQ Dublin, IE Burlington, US | Locations Tucson, US HQ | Locations København, DK HQ | Locations Bundoora, AU HQ München, DE Hummelstown, US |
Employees | Employees 614% decrease | Employees 1061% decrease | Employees 1220% increase | Employees 7 | Employees 20 |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 19.7m | Total funding raised $ 1.6m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Blue Earth Diagnostics
HQ
Oxford, GB
Blue Earth Diagnostics is a molecular imaging diagnostics company.
View companyMicrovascular Therapeutics
HQ
Tucson, US
Employees
12↑ 20% increase
Microvascular Therapeutics (MVT) is a biotechnology company engaged in the development of an ultrasound contrast agent, MVT-100.
View companyCurasight
HQ
København, DK
Employees
7
Curasight is a company engaged in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR).
View company
vivoPharm
HQ
Bundoora, AU
vivoPharm is a company that provides preclinical oncology and immuno-oncology services.
View company